Home › Research › Topics › cerebrospinal
cerebrospinal
834 studies tagged cerebrospinal, dated 1980-07-01 to 2026-10-16. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
Studies
834 studies carry this tag.
Date range
1980 to 2026
Top journals
- Neurology 131
- Alzheimer s & Dementia 37
- JAMA neurology 35
- Alzheimer's research & therapy 28
- Archives of neurology 25
247 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Comparing clinical stages, CSF PDGFRβ levels were increased at the MCI stage (Cohen's d = 0.55 [CI 95% 0.066, 1.0], P = 0.025) compared with NC.
-
Evaluate the performance of emerging Alzheimer disease (AD) plasma biomarkers in a specialty memory clinic.
-
Alzheimer's disease (AD) and frontotemporal dementia (FTD) are the most common forms of dementia globally.
-
Plasma p-tau217 and p-tau231 were most effective in diagnosing aMCI/AD (AUC = 0.95 and 0.93, respectively), while p-tau217, p-tau231 and p-tau181 presented the best differential diagnosis for AD from PSP, FTD and DLB respectively (AUC = 0.84, 0.81 and 0.83). α-synuclein was presented as the best biomarker for PSP variant and behavior variant FTD subtypes (AUC = 0.81 and 0.74, respectively).
-
BackgroundRecently published clinical studies suggest that blood-based biomarker tests (BBMTs) for Alzheimer's disease (AD) provide value, but in the U.S., neither public nor private payers currently cover these tests.
-
Our results emphasize the role of fluid biomarkers in diagnosing dementia in low‐resource settings in South Asians.
-
= 0.81). NfL levels were not significantly associated with GDS-15 in a population of community-dwelling older adults without dementia.
-
Rates of cognitive decline in Alzheimer's disease (AD) are extremely heterogeneous.
-
Baseline plasma NfL was associated with increased risk of dementia/death in the entire cohort.
-
BackgroundC1q is a promoter of the classical pathway of complement and its massive expression may be associated with the development of Alzheimer's disease (AD).
-
Evidence regarding the clinical validity of blood biomarkers of Alzheimer's disease (AD) in the general population is limited.
-
66/100
Despite remarkable progress in the biomarker field in recent years, local validation of plasma biomarkers of Alzheimer’s disease (AD) and dementia is still lacking in Latin America.
-
Alzheimer's disease (AD) is the most common neurodegenerative disorder that leads to progressive cognitive decline and imposes a significant socio-economic burden.
-
The STUB1/CHIP holds promise as a potential biomarker for distinguishing between SCI subjects, AD, and FTD.
-
KL -VSHET may help protect against amyloid pathology, particularly in the presence of APOE ε4, and regardless of APOE status in aMCI-AD.
-
Diet can impact cognitive aging, but comprehensive data from human studies is lacking and the underlying biological mechanisms are still not fully understood.
-
Changes in β-amyloid (Aβ) and hyperphosphorylated tau (T) in brain and cerebrospinal fluid (CSF) precede Alzheimer's disease (AD) symptoms, making the CSF proteome a potential avenue to understand disease pathophysiology and facilitate reliable diagnostics and therapies.
-
We analyzed 1,240 MRIs from 473 patients (age: 69.2 ± 7.4 [range: 49-87]; 32.8% women).
-
Neuroinflammatory biomarkers are associated with AD progression.
-
A total of 156 patients were clinically diagnosed with dementia based on the 2011 NIA-AA criteria, regardless of specific disease etiology, and all exhibited significant brain atrophy on anatomical magnetic resonance imaging (MRI), indicating neuronal injury (N+).
-
These findings suggest that promoting CVH in older adults may help alleviate the burden of neurodegenerative diseases, particularly among Black adults, who are known to experience a higher prevalence of cardiovascular disease.
-
Cerebral amyloid angiopathy (CAA) is driven by vascular Aβ (amyloid-beta) deposition, which can be detected as reduced Aβ species in cerebrospinal fluid (CSF).
-
These findings suggest that PA may help delay cognitive decline by modulating neurodegeneration and AD-specific tau pathologies.
-
45/100
Plasma Aβ 42/40 , p‐tau‐181, and NfL differ in those with CAA and together can discriminate CAA from healthy controls.
-
Soluble N-ethylmaleimide-sensitive factor attachment proteins receptors (SNARE) proteins, such as VAMP-2 and SNAP-25, are implicated in α-synuclein pathophysiology and CSF levels of these proteins are associated with pathophysiological biomarkers and cognitive decline in Alzheimer’s disease (AD).
-
MMSE score showed a positive correlation with the Aβ 1-42 concentrations ( r = 0.485; p r = -0.418; p = 0.002).
-
However, a recent systematic review and meta-analysis did not support differences in orexin-A between AD and controls.
-
and neurogranin changes correlated with sabirnetug-AβO target engagement (p ≤ 0.01).
-
Among the plasma biomarkers, phosphorylated tau (p-tau) 217 exhibited the highest concordance rate with Aβ (2326 of 2571 [90.5%]) and tau (100 of 120 [83.3%]) PET.
-
44/100
and amyloid composite in the context of AD.
-
AD was common in both AD-related syndromes (110/125 [88%]) and FTLD-related syndromes (45/198 [23%]).
-
Late-life depression (LLD) has been linked to increased likelihood of dementia, although mechanisms responsible for this association remain largely unknown.
-
The mean (SD) baseline age of 758 participants was 61.5 (6.1) years, and 424 participants [55.9%] were female.
-
Of 1441 plasma proteins surveyed, a 12-protein signature significantly predicted cognitive decline (q-value < .05).
-
= 0.02, 95% CI -0.07 to -0.01) network connectivity.
-
Plasma biomarkers are promising tools for the screening and diagnosis of dementia in clinical settings.
-
56/100
After adjusting for demographics, apolipoprotein E (APOE) ε4 status, cognition, and comorbidities, the highest tertile of REM latency was associated with higher Aβ burden (β = 0.08, 95% confidence interval [CI]: 0.03 to 0.13, p = 0.002), elevated p-tau181 (β = 0.19, 95% CI: 0.02 to 0.13, p = 0.002), and reduced BDNF levels (β = -0.47, 95% CI: -0.68 to -0.13, p = 0.013), compared to the lowest tertile.
-
Among 4080 participants included in the analysis, the mean (SD) age was 66.5 (8.9) years, and 2241 (54.9%) were female.
-
In vitro and animal studies have suggested that inoculation with herpes simplex virus 1 (HSV-1) can lead to amyloid deposits, hyperphosphorylation of tau, and/or neuronal loss.
-
Apolipoprotein E ε4 (APOE ε4) bring the higher risk of Alzheimer' Disease (AD).
-
42/100
There has been growing interest in the role of biofluid biomarkers to aid the diagnosis of dementia in older people.
-
A Doença de Alzheimer (DA) é a principal causa de demência em idosos, causada pelo acúmulo de β-amiloide e emaranhados neurofibrilares no cérebro.
-
Currently available literature on the relationships between cerebrospinal fluid (CSF) biomarkers and cognitive performance in frontotemporal dementia (FTD) is very limited and inconclusive.
-
The PD-MCI nonreversion group had greater p-tau:amyloid beta and t-tau:amyloid beta ratios relative to the PD-MCI reversion group.
-
Our findings provide preliminary empirical support for a relationship between prodromal changes in retinal layers and a higher risk of AD or FTD, suggesting that macular OCT may serve as a non-invasive, sensitive biomarker of high-risk years before the onset of dementia.
-
43/100
Amyloid‐reactive T cell polyfunctional response distinguishes MCI from normal aging and could serve as a novel MCI biomarker.
-
Clinical Dementia Rating-Global scores (1.44 ± 0.65 versus 0.24 ± 0.25; P < 0.0001) and Patient Health Questionnaire-9 scores (4.88 ± 4.21 versus 0.20 ± 0.50; P < 0.0001) were higher than controls.
-
Vascular burden influences NfL levels, particularly in A- individuals at a symptomatic stage.
-
Postoperative delirium (POD) is often under-recognized in clinical practice.
-
65/100
This study examined whether levels of blood biomarkers of amyloid (Aβ 42 /Aβ 40 ratio), tau (p-tau 181 ), neurodegeneration (NfL), and glial activation and neuroinflammation (glial fibrillary acidic protein [GFAP], YKL40, soluble triggering receptor expressed on myeloid cells 2 [sTREM2]) collected when participants were cognitively normal are associated with the time to onset of MCI.
From across this tag
9 of the 829 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease
- Resting state EEG biomarkers of cognitive decline associated with Alzheimer's disease and mild cognitive impairment
- Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults
- CSF biomarkers in relationship to cognitive profiles in Alzheimer disease
- Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease
- Biomarkers for early detection of Alzheimer disease
- Unravelling the plasma proteome: Pioneering biomarkers for differential dementia diagnosis
- Association of plasma biomarkers with longitudinal change in age- and Alzheimer's disease-related brain atrophy patterns
- Associations between serum cholesterol levels and cerebral amyloidosis